Debulking surgery for patient's with diffuse large B-cell non-Hodgkin's lymphoma

Margarita Tokar, Ronit Yerushalmi, Dmitri Bobilev, Itai Levi, David B. Geffen, Ofer Shpilberg

Research output: Contribution to journalArticlepeer-review

Abstract

Chemotherapy and radiotherapy have been the principal modalities of treatment for diffuse large B-cell non-Hodgkin's lymphoma (B-NHL) for over 30 years. Various treatment regimens have been designed over the years to try to increase response and cure rates. The role of surgery has been generally restricted to defined and limited situations including diagnostic tissue biopsies and treating abdominal emergencies such as organ rupture or perforation. We present two cases of refractory B-NHL, where surgery was used as a part of stepwise and multi-modal treatment with curative intent. In both cases, the treatment approach included standard dose chemotherapy, eradication of residual mass by surgery, high dose chemotherapy (HDC) with stem cell support and posttransplantant immunotherapy. Currently, 2 years after completing the therapy, both patients are well with no evidence of active disease. Based on our experience with 2 patients we believe that in specific cases of residual chemo-resistant lymphomatous mass, surgery should be considered as a part of a multimodal approach.

Original languageEnglish
Pages (from-to)1853-1856
Number of pages4
JournalLeukemia and Lymphoma
Volume45
Issue number9
DOIs
StatePublished - Sep 2004
Externally publishedYes

Keywords

  • Debulking surgery
  • High dose chemotherapy with stem cell support
  • Non-Hodgkin's lymphoma
  • Posttransplantant immunotherapy
  • Residual lymphomatous mass

Fingerprint

Dive into the research topics of 'Debulking surgery for patient's with diffuse large B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this